Zydus life science has announced the completion of its postal ballot voting process for a special resolution, with results declared on December 12, 2025. The pharmaceutical company submitted detailed voting results to both BSE Limited and National Stock Exchange of India Limited, fulfilling its regulatory obligations under the SEBI Listing Regulations.

Postal Ballot Process Details

The company facilitated remote e-voting through Central Depository Services (India) Limited platform for its shareholders. The voting process was structured with specific timelines to ensure maximum participation from eligible shareholders.

Voting Results by Category

The postal ballot results show participation across different shareholder categories, with detailed breakdowns of votes polled and voting patterns. The promoter and promoter group category recorded significant participation in the voting process.

Regulatory Compliance

The company has fulfilled its obligations under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The detailed voting results have been submitted along with the Scrutinizer's Report on remote e-voting to ensure transparency and compliance.

The voting results and related documents are being uploaded on the company's official website for public access. This postal ballot process was conducted without a physical Annual General Meeting, as indicated by the "Not Applicable" status for AGM-related parameters in the official documentation.

Corporate Communication

Dhaval N. Soni, Company Secretary and Compliance Officer (Membership No. FCS7063), signed the official communication to the stock exchanges. The company maintains its registered office at Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), near Vaishnodevi Circle, S.G. Highway, Ahmedabad-382481, Gujarat.

Zydus Lifesciences , a prominent player in the pharmaceutical industry, has announced the launch of Zyrifa, a new bone health drug specifically designed for cancer patients. This strategic move not only broadens the company's oncology portfolio but also addresses a critical healthcare need for patients battling cancer-related skeletal complications.

Product Overview

Zyrifa aims to prevent skeletal problems in cancer patients, a common and often debilitating side effect of both the disease and its treatments. By introducing this specialized medication, Zydus Lifesciences demonstrates its commitment to improving the quality of life for cancer patients.

Market Implications

The launch of Zyrifa could potentially strengthen Zydus Lifesciences' position in the oncology market. By addressing a specific and critical need within cancer care, the company may see increased interest from healthcare providers and patients alike.

Pricing Strategy

At ₹12,495, Zyrifa represents a significant investment in patient care. The price point reflects the potential long-term benefits and cost savings in preventing serious skeletal complications for cancer patients.

The introduction of Zyrifa underscores Zydus Lifesciences' ongoing efforts to innovate in the pharmaceutical space, particularly in areas where patient needs are most pressing. As the company continues to expand its oncology portfolio, this new offering demonstrates the company's focus on addressing critical healthcare challenges in cancer treatment.